Improved Visual Hallucination by Donepezil and Occipital Glucose Metabolism in Dementia with Lewy Bodies: The Osaki-Tajiri Project

Satoh, Masayuki; Ishikawa, Hiroyasu; Meguro, Kenichi; Kasuya, Masashi; Ishii, Hiroshi; Yamaguchi, Satoshi

doi:10.1159/000322121

Cited by 42 publications

(27 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of DLB, previous FDG-PET studies revealed a pattern of hypometabolism in the medial occipital cortex (Klein et al, 2010;Perneczky et al, 2008a;Satoh et al, 2010), in agreement with the previously reported SPECT data of hypoperfusion. Furthermore, other literature data found a correlation between cerebral hypometabolism in right temporoparietal cortex, prefrontal cortex and the precuneus and patients' performance level of everyday competence (Perneczky et al, 2008b;Perneczky et al, 2009a).…”

Section: Positron Emission Tomography (Pet)supporting

confidence: 90%

Neuroimaging Findings in Dementia with Lewy Body: A Review

Baglio¹,

Preti²,

Farina³

2012

Neuroimaging - Methods

View full text Add to dashboard Cite

Section: Positron Emission Tomography (Pet)supporting

confidence: 90%

Neuroimaging Findings in Dementia with Lewy Body: A Review

Baglio¹,

Preti²,

Farina³

2012

Neuroimaging - Methods

View full text Add to dashboard Cite

“…These studies found that donepezil decreased the severity of hallucinations, but found conflicting imaging results, with one reporting occipital perfusion increased after treatment, (Mori et al 2006) but the other decreased glucose metabolism (Satoh et al 2010).…”

Section: Discussionmentioning

confidence: 99%

The relationship between hallucinations and FDG-PET in dementia with Lewy bodies

Firbank

Lloyd

O’Brien

2015

Brain Imaging and Behavior

View full text Add to dashboard Cite

Visual hallucinations are common in dementia with Lewy bodies (DLB), although their etiology is unclear. This study aimed to investigate the relationship between severity and frequency of hallucinations and regional brain glucose metabolism. We performed brain FDG-PET scanning on 28 subjects with DLB (mean age 76). The neuropsychiatric index (NPI) was used to assess frequency and severity of hallucinations. We used the SPM package to investigate voxelwise correlations between NPI hallucination score (severity x frequency) and FDG uptake relative to the cerebellum. There was a bilateral medial occipital region where reduced FDG was associated with increased hallucination severity and frequency. We conclude that the reduced occipital metabolism frequently seen in DLB is associated with frequency and severity of visual hallucinations. Further studies are required to investigate whether this is the result of deficits in top-down or bottom-up visual processing pathways.

show abstract

“…13,26,27 In DLB, occipital hypometabolism correlates with visual hallucinations 28 and improves with acetylcholinesterase inhibitor treatment. 29 The occipital hypometabolism in DLB is independent of Ab load 11 and is thought to be related to impaired cholinergic transmission or synaptic dysfunction associated with a-synuclein. [30][31][32] In addition, occipital hypometabolism is characteristic of posterior cortical atrophy (atypical AD) and advanced AD and thus is not specific for DLB.…”

Section: Antemortemmentioning

confidence: 99%

Dementia with Lewy bodies

et al. 2014

View full text Add to dashboard Cite

Objectives: To investigate clinical, imaging, and pathologic associations of the cingulate island sign (CIS) in dementia with Lewy bodies (DLB).Methods: We retrospectively identified and compared patients with a clinical diagnosis of DLB (n 5 39); patients with Alzheimer disease (AD) matched by age, sex, and education (n 5 39); and cognitively normal controls (n 5 78) who underwent 18 F-fluorodeoxyglucose (FDG) and C11 Pittsburgh compound B (PiB)-PET scans. Among these patients, we studied those who came to autopsy and underwent Braak neurofibrillary tangle (NFT) staging (n 5 10). Dementia with Lewy bodies (DLB) is the second most common cause of dementia.1 Despite revised criteria, 2 clinically distinguishing DLB from other neurodegenerative diseases continues to be problematic. In fact, the National Alzheimer's Coordinating Center registry reported the sensitivity of clinical diagnoses of DLB compared with subsequent pathologic examination to be 32.1%. 3Complicating the inaccuracies of clinical diagnosis, the majority of dementia cases have multiple pathologies at autopsy. 4,5 Coexisting Alzheimer disease (AD) pathology occurs in 51% to 66% of those with pathologically confirmed DLB. 1,6 Accurate antemortem prediction of underlying causes of dementia is important for determining a prognosis, 7,8 predicting treatment response, 9 and planning for clinical trials. Additional biomarkers are required to better distinguish DLB from AD and to predict relative contributions of different underlying pathologies to DLB. By measuring b-amyloid (Ab) deposition with C11 Pittsburgh compound B (PiB) binding, investigators have demonstrated that more than half of patients with DLB have Ab deposition in the brain. 10,11From the Departments of Neurology

show abstract

Improved Visual Hallucination by Donepezil and Occipital Glucose Metabolism in Dementia with Lewy Bodies: The Osaki-Tajiri Project

Cited by 42 publications

References 47 publications

Neuroimaging Findings in Dementia with Lewy Body: A Review

Neuroimaging Findings in Dementia with Lewy Body: A Review

The relationship between hallucinations and FDG-PET in dementia with Lewy bodies

Dementia with Lewy bodies

Contact Info

Product

Resources

About